Differential effects of clozapine and haloperidol on ketamine-induced brain metabolic activation

Subanesthetic doses of N-methyl-d-aspartate (NMDA) receptor antagonists such as ketamine and phencyclidine precipitate psychotic symptoms in schizophrenic patients. In addition, these drugs induce a constellation of behavioral effects in healthy individuals that resemble positive, negative, and cognitive symptoms of schizophrenia. Such findings have led to the hypothesis that decreases in function mediated by NMDA receptors may be a predisposing, or even causative, factor in schizophrenia. The present study examined the effects of the representative atypical (clozapine) and typical (haloperidol) antipsychotic drugs on ketamine- induced increases in [14C]-2-deoxyglucose (2-DG) uptake in the rat brain. As previously demonstrated, administration of subanesthetic doses of ketamine increased 2-DG uptake in specific brain regions, including medial prefrontal cortex, retrosplenial cortex, hippocampus, nucleus accumbens, basolateral amygdala, and anterior ventral thalamic nucleus. Pretreatment of rats with 5 or 10 mg/kg clozapine alone produced minimal or no change in 2-DG uptake, yet clozapine completely blocked ketamine-induced changes in 2-DG uptake in all brain regions studied. In striking contrast, a dose of haloperidol (0.5 mg/kg) that produces a substantial cataleptic response, potentiated, rather than blocked, ketamine-induced activation of 2-DG uptake. These results demonstrate, in a model with potential relevance to schizophrenia, a striking neurobiological difference between the actions of prototypical typical and atypical antipsychotic drugs. The dramatic blockade by clozapine of ketamine-induced brain metabolic activation suggests that antagonism of the consequences of reduced NMDA receptor function could contribute to the superior therapeutic effects of this atypical antipsychotic agent. The results also suggest that this model of ketamine-induced alterations in 2-DG uptake may be extremely useful for understanding the complex neural mechanisms of atypical antipsychotic drug action.

[1]  J. Liu,et al.  Regulation of glutamate efflux by excitatory amino acid receptors: evidence for tonic inhibitory and phasic excitatory regulation. , 1995, The Journal of pharmacology and experimental therapeutics.

[2]  H. Meltzer.  Pre-clinical Pharmacology of Atypical Antipsychotic Drugs: A Selective Review , 1996, British Journal of Psychiatry.

[3]  Carol A. Tamminga,et al.  Subanesthetic Doses of Ketamine Stimulate Psychosis in Schizophrenia , 1995, Neuropsychopharmacology.

[4]  G. Duncan,et al.  Brain activity patterns: Assessment by high resolution autoradiographic imaging of radiolabeled 2-deoxyglucose and glucose uptake , 1991, Progress in Neurobiology.

[5]  S H Snyder,et al.  Drugs, neurotransmitters, and schizophrenia. , 1974, Science.

[6]  Herbert Weingartner,et al.  NMDA Receptor Function and Human Cognition: The Effects of Ketamine in Healthy Volunteers , 1996, Neuropsychopharmacology.

[7]  J. Olney,et al.  Olanzapine and fluperlapine mimic clozapine in preventing MK-801 neurotoxicity , 1996, Schizophrenia Research.

[8]  A. Ceci,et al.  Non-competitive N-methyl-d-aspartate antagonists are potent activators of ventral tegmental A10 dopamine neurons , 1990, Neuroscience Letters.

[9]  G. Breese,et al.  Functional classification of antidepressants based on antagonism of swim stress-induced fos-like immunoreactivity. , 1996, The Journal of pharmacology and experimental therapeutics.

[10]  G. F. Steinfels,et al.  Electrophysiological effects of selective sigma-receptor agonists, antagonists, and the selective phencyclidine receptor agonist MK-801 on midbrain dopamine neurons. , 1989, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.

[11]  P. Williamson,et al.  Neuropsychological correlates of syndromes in schizophrenia , 1997, British Journal of Psychiatry.

[12]  L. Noble,et al.  Haloperidol prevents induction of the hsp70 heat shock gene in neurons injured by phencyclidine (PCP), MK801, and ketamine , 1992, Journal of neuroscience research.

[13]  M. Tricklebank,et al.  The glycine/NMDA receptor antagonist, R‐(+)‐HA‐966, blocks activation of the mesolimbic dopaminergic system induced by phencyclidine and dizocilpine (MK‐801) in rodents , 1993, British journal of pharmacology.

[14]  G. Breese,et al.  Metabolic mapping of the rat brain after subanesthetic doses of ketamine: potential relevance to schizophrenia , 1998, Brain Research.

[15]  G. Breese,et al.  Neuroanatomical characterization of inferior collicular seizure genesis: 2-deoxyglucose and stimulation mapping , 1991, Brain Research.

[16]  F. J. White,et al.  Behavioral sensitization to MK-801 (dizocilpine): neurochemical and electrophysiological correlates in the mesoaccumbens dopamine system. , 1993, Behavioural pharmacology.

[17]  J. Krystal,et al.  Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. , 1994, Archives of general psychiatry.

[18]  Bita Moghaddam,et al.  Activation of Glutamatergic Neurotransmission by Ketamine: A Novel Step in the Pathway from NMDA Receptor Blockade to Dopaminergic and Cognitive Disruptions Associated with the Prefrontal Cortex , 1997, The Journal of Neuroscience.

[19]  G. Duncan,et al.  High-Resolution Autoradiographic Imaging of Brain Activity Patterns with Radiolabeled 2-Deoxyglucose and Glucose , 1990 .

[20]  Rex Y. Wang,et al.  M100907 and Clozapine, but not Haloperidol or Raclopride, Prevent Phencyclidine-Induced Blockade of NMDA Responses in Pyramidal Neurons of the Rat Medial Prefrontal Cortical Slice , 1998, Neuropsychopharmacology.

[21]  K. Davis,et al.  Dopamine in schizophrenia: a review and reconceptualization. , 1991, The American journal of psychiatry.

[22]  B. Angrist,et al.  The phenomenology of experimentally induced amphetamine psychosis--preliminary observations. , 1970, Biological psychiatry.

[23]  P. Seeman,et al.  Atypical Neuroleptics Have Low Affinity for Dopamine D2 Receptors or Are Selective for D4 Receptors , 1997, Neuropsychopharmacology.

[24]  G. Duncan.  High Resolution Autoradiographic Imaging of Brain Activity Patterns with 2-Deoxyglucose: Regional Topographic and Cellular Analysis , 1992 .

[25]  H. Kim,et al.  Differential effects of phencyclidine (PCP) and ketamine on mesocortical and mesostriatal dopamine release in vivo. , 1989, Life sciences.

[26]  B. Moghaddam,et al.  NMDA receptor antagonists impair prefrontal cortex function as assessed via spatial delayed alternation performance in rats: modulation by dopamine , 1996, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[27]  George R. Breese,et al.  Metabolic and functional mapping of the neural network subserving inferior collicular seizure generalization , 1995, Brain Research.

[28]  N. Swerdlow,et al.  Clozapine antagonizes phencyclidine-induced deficits in sensorimotor gating of the startle response. , 1994, The Journal of pharmacology and experimental therapeutics.

[29]  J. Olney,et al.  Antipsychotic drugs block phencyclidine receptor-mediated neurotoxicity , 1993, Biological Psychiatry.

[30]  J. Olney,et al.  Neuronal Vacuolization and Necrosis Induced by the Noncompetitive N-methyl-d-aspartate (NMDA) Antagonist MK(+)801 (Dizocilpine Maleate): A Light and Electron Microscopic Evaluation of the Rat Retrosplenial Cortex , 1993, Experimental Neurology.

[31]  C. Halldin,et al.  Positron Emission Tomography of in-vivo Binding Characteristics of Atypical Antipsychotic Drugs , 1996, British Journal of Psychiatry.

[32]  C. Bakker,et al.  Observations on the psychotomimetic effects of Sernyl. , 1961, Comprehensive psychiatry.

[33]  D. Javitt,et al.  Recent advances in the phencyclidine model of schizophrenia. , 1991, The American journal of psychiatry.

[34]  J. Olney,et al.  Glutamate receptor dysfunction and schizophrenia. , 1995, Archives of general psychiatry.

[35]  A. Carlsson,et al.  Interactions between glutamatergic and monoaminergic systems within the basal ganglia-implications for schizophrenia and Parkinson's disease , 1990, Trends in Neurosciences.

[36]  J. Sharp,et al.  DNQX inhibits phencyclidine (PCP) and ketamine induction of the hsp70 heat shock gene in the rat cingulate and retrosplenial cortex , 1995, Brain Research.

[37]  V. Klimek,et al.  MK-801 elevates the etracellular concentration of dopamine in the rat prefrontal cortex and increases the density of striatal dopamine D1 receptors , 1993, Brain Research.

[38]  F. Sharp,et al.  Haloperidol Prevents Ketamine- and Phencyclidine-Induced HSP70 Protein Expression but Not Microglial Activation , 1996, Experimental Neurology.

[39]  S. Deutsch,et al.  A "glutamatergic hypothesis" of schizophrenia. Rationale for pharmacotherapy with glycine. , 1989, Clinical neuropharmacology.

[40]  L. Zuck,et al.  Glutamate agonist activity: implications for antipsychotic drug action and schizophrenia , 1995, Neuroreport.

[41]  E F Domino,et al.  Dissociative Anesthesia: Further Pharmacologic Studies and First Clinical Experience with the Phencyclidine Derivative Cl‐581 , 1966, Anesthesia and analgesia.

[42]  R. Roth,et al.  Regulation of excitatory amino acid release by N-methyl-d-aspartate receptors in rat striatum: in vivo microdialysis studies , 1992, Brain Research.

[43]  J. Oates,et al.  Dextroamphetamine. Evaluation of psychomimetic properties in man. , 1972, Archives of general psychiatry.

[44]  P. Goldman-Rakic,et al.  Functional and anatomical aspects of prefrontal pathology in schizophrenia. , 1997, Schizophrenia bulletin.

[45]  G. Paxinos,et al.  The Rat Brain in Stereotaxic Coordinates , 1983 .

[46]  S. Stahl,et al.  The dopamine hypothesis of schizophrenia: a review. , 1976, Schizophrenia bulletin.

[47]  G. Rosenbaum,et al.  Study of a new schizophrenomimetic drug; sernyl. , 1959, A.M.A. archives of neurology and psychiatry.

[48]  H. Meltzer,et al.  Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. , 1989, The Journal of pharmacology and experimental therapeutics.

[49]  B. Bunney,et al.  The effects of phencyclidine and N-allylnormetazocine on midbrain dopamine neuronal activity. , 1984, European journal of pharmacology.

[50]  D R Medoff,et al.  Ketamine activates psychosis and alters limbic blood flow in schizophrenia , 1995, Neuroreport.

[51]  G. Buzsáki,et al.  MK-801-induced neuronal damage in rats , 1997, Brain Research.

[52]  N. Tashiro,et al.  Effect of phenycyclidine on dopamine release in the rat prefrontal cortex; an in vivo microdialysis study , 1994, Brain Research.

[53]  A. Imperato,et al.  NMDA receptors and in vivo dopamine release in the nucleus accumbens and caudatus. , 1990, European journal of pharmacology.

[54]  S. Grossman,et al.  Clozapine and haloperidol modulate N-methyl-D-aspartate- and non-N-methyl-D-aspartate receptor-mediated neurotransmission in rat prefrontal cortical neurons in vitro. , 1997, The Journal of pharmacology and experimental therapeutics.

[55]  A. Malhotra,et al.  Clozapine Blunts N-Methyl-d-Aspartate Antagonist-Induced Psychosis: A Study with Ketamine , 1997, Biological Psychiatry.

[56]  C. J. Schmidt,et al.  Regional effects of MK-801 on dopamine release: effects of competitive NMDA or 5-HT2A receptor blockade. , 1996, The Journal of pharmacology and experimental therapeutics.

[57]  K. Johnson,et al.  Topographic patterns of brain activity in response to swim stress: assessment by 2-deoxyglucose uptake and expression of Fos-like immunoreactivity , 1993, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[58]  Anil K Malhotra,et al.  Ketamine-Induced Exacerbation of Psychotic Symptoms and Cognitive Impairment in Neuroleptic-Free Schizophrenics , 1997, Neuropsychopharmacology.

[59]  J. Olney,et al.  NMDA antagonist neurotoxicity: mechanism and prevention. , 1991, Science.

[60]  H. Beech,et al.  The effect of 1-arylcylohexylamine (sernyl) on twelve normal volunteers. , 1960, The Journal of mental science.

[61]  S. Narayanan,et al.  The role of dopamine and AMPA/kainate receptors in the nucleus accumbens in the hypermotility response to MK801 , 1993, Pharmacology Biochemistry and Behavior.